Escobar named hemophilia physician of the year
Miguel A. Escobar, MD, professor in the Department of儿科andInternal Medicine, is the winner of Physician of the Year 2021 from the National Hemophilia Foundation.
Escobar, who also serves as medical director of the Gulf States Hemophilia and Thrombophilia Center, recently received the award at the annual National Hemophilia Foundation meeting, which was held virtually this year in August.
The Physician of the Year award is named in honor ofKenneth Brinkhous, MD, and recognizes a distinguished physician who has had a major impact on the lives of individuals with bleeding disorders. Recipients of the award are those who show compassion and knowledge of the latest treatments, advocate for patients, and are committed caregivers whose concern for patients is at the forefront.
“I have dedicated my professional career to helping hemophilia patients and it is an honor to receive this nomination. This award is not possible without giving credit to my entire team of collaborators at the Gulf States Hemophilia & Thrombophilia Center,” Escobar said.
从环宇Escobar获得医学学位idad Libre, School of Medicine in Cali, Colombia, and his postgraduate training included an internal medicine residency at the University of Connecticut Health Center and a hematology/oncology fellowship at the University of North Carolina at Chapel Hill. He joined the Medical School faculty in 2002 as an assistant professor of internal medicine and pediatrics. He has served as director of the Clinical Research Center since 2016 and is an attending physician at LBJ General Hospital and Memorial Hermann-Texas Medical Center, where he is also director of the Medication Therapy and Wellness Center.
Beyond the hospital and clinic, Escobar serves the community and patients as the attending physician at the Women with Bleeding Disorders Camp, since 2002, and was the medical director of the hemophilia camp, Camp Ailihpomeh, from 2009-13. He has been a volunteer for the World Federation of Hemophilia since 1999 and presently is the chair of the International Hemophilia Treatment Centers Committee for the World Federation of Hemophilia and a board director since 2020, co-chair of the Scientific and Standardization Subcommittee on FVIII/FIX & Rare Coagulation Disorders for the International Society of Thrombosis and Hemostasis.
His research includes multi-national and global studies evaluating the safest, most effective treatments for hemophilia patients, including gene therapy and has published extensively in the area of bleeding and clotting disorders. He mentors students and post doctorates, training the next generation of hemophilia leaders.
Founded in 1948, theNational Hemophilia Foundationis dedicated to finding cures for inheritable blood disorders and to addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.